AMLo Biosciences is a UK-based company formed in late 2017

We are dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify patients true risk of disease progression. Those patients who are genuinely at low-risk of disease spread can be provided reassurance and better-informed follow up care, while those identified at risk of metastasis are enabled to receive timely treatment.

The test under development will be simple to use and fits seamlessly into current diagnostic practice. AMLo Biosciences has been founded by a team with an internationally acclaimed research track record in the melanoma field, through identification of translational biomarkers, drug discovery and development and the building of biotech companies.